Какова цена за Lipidor AB (publ) (LIPI)

Цена за Lipidor AB (publ) (LIPI) Это $0.02243487

Какова рыночная капитализация для Lipidor AB (publ) (LIPI)

Рыночная капитализация для Lipidor AB (publ) (LIPI) Это $650.09K

Прибыль Lipidor AB (publ) (LIPI)

Lipidor AB (publ), a Swedish pharmaceutical company founded in Danderyd in 2009, specializes in developing medicinal products. Its core business centers on creating treatments for various skin conditions, including psoriasis, bacterial skin infections, and atopic dermatitis. The company's product pipeline includes AKP-01, which is currently in Phase III clinical trials for psoriasis, while other formulations like AKP-02 (also for psoriasis) and AKP-03 and AKP-07 (for eczema) are in earlier, preclinical development stages. Beyond its own drug candidates, Lipidor manufactures and supplies active pharmaceutical ingredients (APIs). These APIs are incorporated into products addressing a broad spectrum of therapeutic applications, such as managing psoriasis, microbial infections, inflammation, fungal issues, local pain relief, acne, wound healing, eczema, and migraines. Lipidor also caters to the animal health market, offering a line of spray-on skin care products for dogs, cats, and horses. Additionally, it develops consumer health items designed for purposes like antibacterial action, antiseptic care, moisturizing, disinfection, and treating acne and warts. In a key strategic alliance, Lipidor has partnered with Cannassure Therapeutics Ltd. This collaboration aims to advance topical medicinal cannabis products specifically formulated to alleviate skin inflammations and psoriatic lesions.

Год	Прибыль	Изменить
2026 (TTM)	$-1.25M	0.00%
2024	$-1.25M	9.96%
2023	$-1.14M	-71.31%
2022	$-3.97M	68.68%
2021	$-2.35M	19.98%
2020	$-1.96M	32.57%
2019	$-1.48M	73.02%
2018	$-854.84K	129.77%
2017	$-372.04K	-30.69%
2016	$-536.78K	0.00%

Год

Прибыль

Изменить

2026 (TTM)

$-1.25M

0.00%

2024

$-1.25M

9.96%

2023

$-1.14M

-71.31%

2022

$-3.97M

68.68%

2021

$-2.35M

19.98%

2020

$-1.96M

32.57%

2019

$-1.48M

73.02%

2018

$-854.84K

129.77%

2017

$-372.04K

-30.69%

2016

$-536.78K

0.00%

Компания	Прибыль	Разница в прибыли	Страна
Eli Lilly and Company LLY.US	$33.59B	-2,683,842.70%	US
Johnson & Johnson JNJ.US	$25.20B	-2,012,923.00%	US
AbbVie Inc. ABBV.US	$8.70B	-695,033.61%	US
Roche Holding AG RO.SW	$21.39B	-1,708,738.18%	CH
Merck & Co., Inc. MRK.US	$5.95B	-475,265.55%	US

Компания

Прибыль

Разница в прибыли

Страна